Multicenter phase 1b/II trial testing neoadjuvant intradermal Ipilimumab and Nivolumab in high risk stage II melanoma –MARIANE

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505945-19-00

Acronym

M23MAR

Enrollment

106

Registered

2024-02-05

Start date

2024-03-08

Completion date

Unknown

Last updated

2025-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stage II melanoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Netherlands, Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026